This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Brookdale Senior Living (BKD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Brookdale (BKD) delivered earnings and revenue surprises of -28.57% and -0.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Ensign Group (ENSG) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of +3.25% and +1.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Brookdale's Occupancy Registers a Rise to 80.5% in June 2025
by Zacks Equity Research
BKD's June occupancy improves 230 bps year over year to 80.5%, driven by stronger move-ins and move-out activity across its senior living communities.
Brookdale Shares Down 4.9% Despite Q1 Earnings Meeting Estimates
by Zacks Equity Research
BKD continues to witness growth in revenue per available unit (RevPAR). It increases its EBITDA range for 2025.
Brookdale Senior Living (BKD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Brookdale (BKD) delivered earnings and revenue surprises of 0% and 0.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Brookdale Senior Living (BKD) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Ensign Group (ENSG) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.33% and 0.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Take the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Brookdale Senior Living (BKD) and Claritev Corporation (CTEV) have performed compared to their sector so far this year.
Has HCA Healthcare (HCA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how HCA Healthcare (HCA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Why Fast-paced Mover Brookdale (BKD) Is a Great Choice for Value Investors
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Brookdale (BKD) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Wall Street Analysts See a 25.3% Upside in Brookdale (BKD): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 25.3% upside potential for Brookdale (BKD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Should Value Investors Buy Brookdale Senior Living (BKD) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Brookdale Senior Living (BKD) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Despite Fast-paced Momentum, Brookdale (BKD) Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Brookdale (BKD) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here's What Brookdale's Occupancy Growth Story Tells Us
by Zacks Equity Research
BKD is likely to have witnessed 40 straight months of year-over-year increases in weighted average occupancy.
Brookdale Expands Real Estate Portfolio With Strategic Acquisitions
by Zacks Equity Research
BKD expands its real estate footprint with the closure of two acquisitions.
Brookdale Incurs Loss in Q4 Due to Higher Costs, Shares Up 6%
by Zacks Equity Research
BKD's Q4 results reflect escalating general and administrative costs, partly offset by improved occupancy rates. It projects 2025 adjusted EBITDA within $430-$445 million.
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Guardant Health (GH) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Brookdale (BKD) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Brookdale (BKD) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Wall Street Analysts Believe Brookdale (BKD) Could Rally 35.41%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 35.4% in Brookdale (BKD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Should Value Investors Buy Brookdale Senior Living (BKD) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should You Buy, Sell or Hold Pediatrix Medical Stock at a 9.28X P/E?
by Zacks Equity Research
Stable same-facility patient volume growth, inorganic initiatives and transition to an RCM structure should aid MD's future growth.
Brookdale's 37-Month Growth Streak: Is BKD Stock a Safe Bet?
by Zacks Equity Research
BKD's weighted average occupancy for November grows 10 bps sequentially.
Brookdale Q3 Earnings Miss on Marketing Cost Hike, Shares Decline 18%
by Zacks Equity Research
BKD's Q3 results reflect higher marketing costs and lower interest income. Revenues and other operating income improve 3.5% year over year, driven by increased occupancy and RevPOR.